Workflow
Can Chain Bridge Bancorp, Inc. (CBNA) Run Higher on Rising Earnings Estimates?
ZACKS· 2025-08-13 17:21
Chain Bridge Bancorp, Inc. (CBNA) appears an attractive pick given a noticeable improvement in the company's earnings outlook. The stock has been a strong performer lately, and the momentum might continue with analysts still raising their earnings estimates for the company.The upward trend in estimate revisions for this company reflects growing optimism of analysts on its earnings prospects, which should get reflected in its stock price. After all, empirical research shows a strong correlation between trend ...
Surging Earnings Estimates Signal Upside for Columbia Banking (COLB) Stock
ZACKS· 2025-08-13 17:21
Columbia Banking (COLB) could be a solid addition to your portfolio given a notable revision in the company's earnings estimates. While the stock has been gaining lately, the trend might continue since its earnings outlook is still improving.Analysts' growing optimism on the earnings prospects of this bank holding company is driving estimates higher, which should get reflected in its stock price. After all, empirical research shows a strong correlation between trends in earnings estimate revisions and near- ...
Why Integral Ad Science (IAS) Might be Well Poised for a Surge
ZACKS· 2025-08-13 17:21
Integral Ad Science (IAS) could be a solid addition to your portfolio given a notable revision in the company's earnings estimates. While the stock has been gaining lately, the trend might continue since its earnings outlook is still improving.The upward trend in estimate revisions for this digital advertising verification company reflects growing optimism of analysts on its earnings prospects, which should get reflected in its stock price. After all, empirical research shows a strong correlation between tr ...
Surging Earnings Estimates Signal Upside for New York Times (NYT) Stock
ZACKS· 2025-08-13 17:21
Investors might want to bet on New York Times Co. (NYT) , as earnings estimates for this company have been showing solid improvement lately. The stock has already gained solid short-term price momentum, and this trend might continue with its still improving earnings outlook.The rising trend in estimate revisions, which is a result of growing analyst optimism on the earnings prospects of this newspaper publisher, should get reflected in its stock price. After all, empirical research shows a strong correlatio ...
Can Ponce Financial (PDLB) Run Higher on Rising Earnings Estimates?
ZACKS· 2025-08-13 17:21
Ponce Financial (PDLB) could be a solid choice for investors given the company's remarkably improving earnings outlook. While the stock has been a strong performer lately, this trend might continue since analysts are still raising their earnings estimates for the company.Analysts' growing optimism on the earnings prospects of this holding company of Ponce Bank is driving estimates higher, which should get reflected in its stock price. After all, empirical research shows a strong correlation between trends i ...
Why Thryv (THRY) Might be Well Poised for a Surge
ZACKS· 2025-08-13 17:21
Thryv Holdings, Inc. (THRY) could be a solid choice for investors given the company's remarkably improving earnings outlook. While the stock has been a strong performer lately, this trend might continue since analysts are still raising their earnings estimates for the company.The rising trend in estimate revisions, which is a result of growing analyst optimism on the earnings prospects of this company, should get reflected in its stock price. After all, empirical research shows a strong correlation between ...
Earnings Estimates Rising for TowneBank (TOWN): Will It Gain?
ZACKS· 2025-08-13 17:21
TowneBank (TOWN) could be a solid addition to your portfolio given a notable revision in the company's earnings estimates. While the stock has been gaining lately, the trend might continue since its earnings outlook is still improving.The upward trend in estimate revisions for this community bank reflects growing optimism of analysts on its earnings prospects, which should get reflected in its stock price. After all, empirical research shows a strong correlation between trends in earnings estimate revisions ...
Earnings Estimates Moving Higher for Envista (NVST): Time to Buy?
ZACKS· 2025-08-13 17:21
Envista (NVST) appears an attractive pick given a noticeable improvement in the company's earnings outlook. The stock has been a strong performer lately, and the momentum might continue with analysts still raising their earnings estimates for the company.The rising trend in estimate revisions, which is a result of growing analyst optimism on the earnings prospects of this maker of dental products, should get reflected in its stock price. After all, empirical research shows a strong correlation between trend ...
Dundee Precious Metals Announces Overwhelming Shareholder Approval for Acquisition of Adriatic Metals and Name Change
Globenewswire· 2025-08-13 17:17
TORONTO, Aug. 13, 2025 (GLOBE NEWSWIRE) -- Dundee Precious Metals Inc. (TSX: DPM) (“DPM”) is pleased to announce the voting results from its special meeting (the “Meeting”) of DPM shareholders (“Shareholders”) held at 10:00 a.m. (Toronto time) on August 13, 2025. At the Meeting, Shareholders voted to approve both (i) the issuance (the “Share Issuance”) of common shares of DPM (“DPM Shares”) in connection with DPM’s proposed acquisition (the “Acquisition”) of the issued and to be issued ordinary shares of Ad ...
Nuvalent to Present Pivotal Data from ARROS-1 Clinical Trial of Zidesamtinib for TKI Pre-treated Patients with Advanced ROS1-positive NSCLC at WCLC 2025 Presidential Symposium
Prnewswire· 2025-08-13 17:06
CAMBRIDGE, Mass., Aug. 13, 2025 /PRNewswire/ -- Nuvalent, Inc. (Nasdaq: NUVL), a clinical-stage biopharmaceutical company focused on creating precisely targeted therapies for clinically proven kinase targets in cancer, today announced that pivotal data for zidesamtinib, a novel ROS1-selective inhibitor, in TKI (tyrosine kinase inhibitor) pre-treated patients with advanced ROS1-positive non-small cell lung cancer (NSCLC) from the global ARROS-1 Phase 1/2 clinical trial, in addition to preliminary data for TK ...